OncoMatch/Clinical Trials/NCT06503094
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Is NCT06503094 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CD19&CD20 bispecific CAR-T cells for b-cell lymphoblastic leukemia/lymphoma.
Treatment: CD19&CD20 bispecific CAR-T cells — This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD20 bispecific CAR-T cells in relapsed / refractory B cell hematological tumors while collecting pharmacokinetics and pharmacodynamics indicators of CAR-T cells.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression (positive)
The results of FCM or immunohistochemical detection of tumor antigen (CD 19 / CD 20) were positive.
Required: CD20 overexpression (positive)
The results of FCM or immunohistochemical detection of tumor antigen (CD 19 / CD 20) were positive.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: monoclonal antibody against CD20
Subject must have received prior adequate treatment, including at least: a monoclonal antibody against CD 20 and combination chemotherapy containing an anthracycline drug agent.
Must have received: anthracycline
combination chemotherapy containing an anthracycline drug agent
Lab requirements
Liver function
Active hepatitis (hepatitis B virus deoxyribonucleic acid [HBV-DNA 500 IU / ml and abnormal liver function] or hepatitis C antibody [HCV-Ab] positive, HCV-RNA above the lower limit of detection of the analytical method and abnormal liver function) [excluded]
Cardiac function
Appearance of one of the following cardiac criteria: atrial fibrillation; myocardial infarction in the last 12 months; prolonged QT syndrome or secondary QT extension, as judged by the investigator. Echocardiography LVSF <30% or LVEF <50%; clinically significant pericardial effusion; cardiac insufficiency NYHA III or IV (confirmed by echocardiography within 12 months of treatment).
Appearance of one of the following cardiac criteria: atrial fibrillation; myocardial infarction in the last 12 months; prolonged QT syndrome or secondary QT extension, as judged by the investigator. Echocardiography LVSF <30% or LVEF <50%; clinically significant pericardial effusion; cardiac insufficiency NYHA (New York Heart Association) III or IV (confirmed by echocardiography within 12 months of treatment). Active hepatitis (hepatitis B virus deoxyribonucleic acid [HBV-DNA 500 IU / ml and abnormal liver function] or hepatitis C antibody [HCV-Ab] positive, HCV-RNA above the lower limit of detection of the analytical method and abnormal liver function).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06503094 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received monoclonal antibody against CD20 and anthracycline.
Does this trial require CD19?
Yes, CD19 overexpression is a required biomarker for enrollment.
Does this trial require CD20?
Yes, CD20 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify